Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an …

AV Khera, BM Everett, MP Caulfield, FM Hantash… - Circulation, 2014 - Am Heart Assoc
Background— Lipoprotein(a) [Lp(a)] is a low-density lipoprotein–like particle largely independent
of known risk factors and predictive of cardiovascular disease. Statins may offset the …

Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study

…, G Engström, A Gottsäter, MP Caulfield… - Journal of the …, 2015 - Am Heart Assoc
Background Community screening to guide preventive interventions for acute aortic disease
has been recommended in high‐risk individuals. We sought to prospectively assess risk …

Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis

MP Caulfield, S Li, G Lee, PJ Blanche… - Clinical …, 2008 - academic.oup.com
Background: Current methods for measuring the concentrations of lipoprotein particles and
their distributions in particle subpopulations are not standardized. We describe here and …

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk

…, M Orho-Melander, MP Caulfield… - … , and vascular biology, 2009 - Am Heart Assoc
Objective— Whereas epidemiological studies show that levels of low-density lipoprotein
cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) predict incident …

Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes

F Bril, MJ McPhaul, MP Caulfield, VC Clark… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE The 2019 Standards of Medical Care in Diabetes suggested that patients with
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …

Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the …

S Mora, MP Caulfield, J Wohlgemuth, Z Chen… - Circulation, 2015 - Am Heart Assoc
Background— Cardiovascular disease (CVD) can occur in individuals with low low-density
lipoprotein (LDL) cholesterol (LDL-C). We investigated whether detailed measures of LDL …

Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges

…, NJ Clarke, RE Reitz, MP Caulfield - Steroids, 2010 - Elsevier
Accurate measurement of testosterone concentration is of critical importance when diagnosing
and treating male hypogonadism, congenital adrenal hyperplasia, premature or delayed …

Cyclic parathyroid hormone-related protein antagonists: Lysine 13 to aspartic acid 17 [i to (i+ 4)] side chain to side chain lactamization

…, SW Gibbons, ME Goldman, MP Caulfield… - Biochemistry, 1991 - ACS Publications
(A" b= 15 and 18 nM in PTH receptor binding assays, and Kt= 130 and 17 nM in PTH-stimulated
adenylate cyclase assays in bovine renal cortical membraneand in human bone derived …

The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens

MP Caulfield, T Lynn, ME Gottschalk… - The Journal of …, 2002 - academic.oup.com
Definitive neonatal diagnosis of congenital adrenal hyperplasia (CAH) is frequently complicated
by normal 17-hydroxyprogesterone levels in 21-hydroxylase-deficient patients, residual …

Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro

N Horiuchi, MP Caulfield, JE Fisher, ME Goldman… - Science, 1987 - science.org
One mechanism considered responsible for the hypercalcemia that frequently accompanies
malignancy is secretion by the tumor of a circulating factor that alters calcium metabolism. …